vs
Amphastar Pharmaceuticals, Inc.（AMPH）とUSA Compression Partners, LP（USAC）の財務データ比較。上の社名をクリックして会社を切り替えられます
USA Compression Partners, LPの直近四半期売上が大きい（$252.5M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.4倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 11.0%、差は2.3%）。USA Compression Partners, LPの前年同期比売上増加率が高い（2.7% vs -1.8%）。USA Compression Partners, LPの直近四半期フリーキャッシュフローが多い（$87.7M vs $24.6M）。過去8四半期でUSA Compression Partners, LPの売上複合成長率が高い（4.9% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
USA Compression Partners, LPは米国に本拠を置く天然ガス圧縮サービスプロバイダーであり、石油・ガス業界の上流・中流・下流分野の顧客向けに、カスタム圧縮システム、保守サービス、運用支援を提供し、天然ガスの生産・加工・輸送の効率化を支えています。
AMPH vs USAC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $252.5M |
| 純利益 | $24.4M | $27.8M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 30.3% |
| 純利益率 | 13.3% | 11.0% |
| 売上前年比 | -1.8% | 2.7% |
| 純利益前年比 | -35.7% | 9.1% |
| EPS（希薄化後） | $0.51 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $252.5M | ||
| Q3 25 | $191.8M | $250.3M | ||
| Q2 25 | $174.4M | $250.1M | ||
| Q1 25 | $170.5M | $245.2M | ||
| Q4 24 | $186.5M | $245.9M | ||
| Q3 24 | $191.2M | $240.0M | ||
| Q2 24 | $182.4M | $235.3M | ||
| Q1 24 | $171.8M | $229.3M |
| Q4 25 | $24.4M | $27.8M | ||
| Q3 25 | $17.4M | $34.5M | ||
| Q2 25 | $31.0M | $28.6M | ||
| Q1 25 | $25.3M | $20.5M | ||
| Q4 24 | $38.0M | $25.4M | ||
| Q3 24 | $40.4M | $19.3M | ||
| Q2 24 | $37.9M | $31.2M | ||
| Q1 24 | $43.2M | $23.6M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 30.3% | ||
| Q3 25 | 13.2% | 33.5% | ||
| Q2 25 | 24.2% | 30.6% | ||
| Q1 25 | 21.9% | 28.3% | ||
| Q4 24 | 24.2% | 30.3% | ||
| Q3 24 | 29.8% | 31.5% | ||
| Q2 24 | 30.3% | 32.9% | ||
| Q1 24 | 27.9% | 29.2% |
| Q4 25 | 13.3% | 11.0% | ||
| Q3 25 | 9.0% | 13.8% | ||
| Q2 25 | 17.8% | 11.4% | ||
| Q1 25 | 14.8% | 8.4% | ||
| Q4 24 | 20.4% | 10.3% | ||
| Q3 24 | 21.1% | 8.1% | ||
| Q2 24 | 20.8% | 13.3% | ||
| Q1 24 | 25.1% | 10.3% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.64 | — | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | — | ||
| Q2 24 | $0.73 | — | ||
| Q1 24 | $0.81 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $8.6M |
| 総負債低いほど良い | $608.7M | $2.5B |
| 株主資本純資産 | $788.8M | — |
| 総資産 | $1.6B | $2.6B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $8.6M | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | $2.0K | ||
| Q1 25 | $236.9M | $2.0K | ||
| Q4 24 | $221.6M | $14.0K | ||
| Q3 24 | $250.5M | $79.0K | ||
| Q2 24 | $217.8M | $9.0K | ||
| Q1 24 | $289.6M | $8.0K |
| Q4 25 | $608.7M | $2.5B | ||
| Q3 25 | $608.6M | $2.5B | ||
| Q2 25 | $607.7M | $2.5B | ||
| Q1 25 | $603.9M | $2.5B | ||
| Q4 24 | $601.6M | $2.5B | ||
| Q3 24 | $596.4M | $2.5B | ||
| Q2 24 | $586.9M | $2.5B | ||
| Q1 24 | $594.0M | $2.5B |
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | — | ||
| Q2 25 | $757.5M | — | ||
| Q1 25 | $751.3M | — | ||
| Q4 24 | $732.3M | — | ||
| Q3 24 | $727.7M | — | ||
| Q2 24 | $713.3M | — | ||
| Q1 24 | $672.4M | — |
| Q4 25 | $1.6B | $2.6B | ||
| Q3 25 | $1.7B | $2.7B | ||
| Q2 25 | $1.6B | $2.7B | ||
| Q1 25 | $1.6B | $2.7B | ||
| Q4 24 | $1.6B | $2.7B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.5B | $2.8B | ||
| Q1 24 | $1.6B | $2.8B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $139.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $87.7M |
| FCFマージンFCF / 売上 | 13.4% | 34.8% |
| 設備投資強度設備投資 / 売上 | 4.5% | 20.5% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 5.02× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $277.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $139.5M | ||
| Q3 25 | $52.6M | $75.9M | ||
| Q2 25 | $35.6M | $124.2M | ||
| Q1 25 | $35.1M | $54.7M | ||
| Q4 24 | $29.0M | $130.2M | ||
| Q3 24 | $60.0M | $48.5M | ||
| Q2 24 | $69.1M | $96.7M | ||
| Q1 24 | $55.3M | $65.9M |
| Q4 25 | $24.6M | $87.7M | ||
| Q3 25 | $47.2M | $51.9M | ||
| Q2 25 | $25.0M | $101.1M | ||
| Q1 25 | $24.4M | $36.3M | ||
| Q4 24 | $16.6M | $101.2M | ||
| Q3 24 | $46.2M | $19.8M | ||
| Q2 24 | $63.1M | $48.2M | ||
| Q1 24 | $46.5M | $-32.7M |
| Q4 25 | 13.4% | 34.8% | ||
| Q3 25 | 24.6% | 20.7% | ||
| Q2 25 | 14.3% | 40.4% | ||
| Q1 25 | 14.3% | 14.8% | ||
| Q4 24 | 8.9% | 41.1% | ||
| Q3 24 | 24.1% | 8.2% | ||
| Q2 24 | 34.6% | 20.5% | ||
| Q1 24 | 27.1% | -14.3% |
| Q4 25 | 4.5% | 20.5% | ||
| Q3 25 | 2.8% | 9.6% | ||
| Q2 25 | 6.1% | 9.3% | ||
| Q1 25 | 6.3% | 7.5% | ||
| Q4 24 | 6.7% | 11.8% | ||
| Q3 24 | 7.2% | 12.0% | ||
| Q2 24 | 3.3% | 20.6% | ||
| Q1 24 | 5.1% | 43.0% |
| Q4 25 | 1.35× | 5.02× | ||
| Q3 25 | 3.03× | 2.20× | ||
| Q2 25 | 1.15× | 4.35× | ||
| Q1 25 | 1.39× | 2.66× | ||
| Q4 24 | 0.76× | 5.12× | ||
| Q3 24 | 1.48× | 2.51× | ||
| Q2 24 | 1.82× | 3.10× | ||
| Q1 24 | 1.28× | 2.80× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
USAC
| Revenue From Contract Operations Excluding Revenue From Related Party | $231.7M | 92% |
| Entities Affiliated With Energy Transfer LP | $16.6M | 7% |
| Transferred At Point In Time | $5.4M | 2% |
